Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Aids : Effectiveness of antiretroviral therapy demonstrated in Africa

28.06.2002


Tritherapies using antiretroviral drugs have proved their worth in industrialized countries in the fight against Aids. However, in Sub-Saharan Africa, where 70 % of people infected with HIV live, access to such treatments is extremely limited. High cost, complicated procedures, combined with inadequate infrastructures for following up patients or capable of delivering medicines regularly partly explain this situation. Moreover, efficacy of antiretroviral agents might not be the same for some HIV strains present in Africa. And not enough is yet known about the response to therapy (viral resistance, adverse effects and so on), notably in patients in advanced stages of immune deficiency. These factors are considered as obstacles to mounting concerted therapy programmes in Africa. For some government authorities they provide the arguments for concentrating control campaigns solely on prevention with no involvement of antiretroviral drugs.



Since 1998 the Senegalese government has been developing a programme facilitating access to Aids treatments (1). Within this, an assessment programme, coordinated by the IRD and the Senegal National Committee for Aids Control, and financed by the Agence nationale de recherches sur le sida (ANRS), has been deployed aiming to determine the effectiveness, the tolerance, the acceptability and feasibility of the standard form of antiretroviral therapy. This study was conducted in a cohort of 58 patients aged between 16 and 56 years, having high viral load and low CD4 cell count. Most of them (86.2%) had developed the disease before the start of the antiretroviral therapy. All received a combination treatment of two nucleoside reverse transcriptase inhibitors plus one protease inhibitor (2) The drugs were taken in three doses per day, just as in the industrialized countries. A sociological survey was done in parallel which assessed patients’ ability to contribute to part of the cost of the treatment depending on their financial resources. The rest would be subsidized by the programme.

At the end of the 18 month study, the results were comparable with those obtained in the countries of the North. Most patients (87.9 %) regularly followed the course of treatment over the whole period monitored. Also, contrary to prior assumptions, financial difficulties did not hinder adherence to the therapy. Furthermore, the same therapeutic efficacy was observed here as in the industrialized countries. After a year and a half of treatment the viral load was almost undetectable (below 500 copies/ml) in 59.3 % of cases and the CD4 cell count had risen markedly (about 180/mm3). Tolerance to antiretroviral medicines was generally good, adverse effects observed being only mild. Only two cases of viral resistance to the drugs were found.


This study gives proof that the therapeutic strategies developed in the industrialized countries can also be applied in Africa. The Senegalese initiative shows that this tritherapy method proves to be effective for most patients, even if their immunity deficiency is severe before embarking on antiretroviral treatments - and although many different strains of HIV-1 are circulating. It must be emphasized also that, contrary to results of several other studies conducted in Africa, viral resistance was rare. The researchers consider that the quality of follow-up of patients under the therapy regimens, attained by involving social workers and the regularity of medicine supply, contributed to the effectiveness. Judging by the excellent results obtained during this pilot phase, it now remains to ascertain that antiretroviral therapy maintains its efficacy over the long term and on a larger scale.

(1) Senegal, which launched its HAART in 1998, was among the first African countries, along with the Ivory Coast and Uganda, to set up a nation-wide programme to facilitate access to treatment for Aids.

(2) These antiretroviral drugs are active against two HIV targets : reverse transcriptase and protease. Both are enzymes. The first enables the viral RNA to transform into DNA so it can then become integrated with the DNA of the cell it infects. Protease builds up the constituent elements of the HIV, before it is released from the cell to spread further.


Marie-Lise Sabrie | alfa

More articles from Health and Medicine:

nachricht Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Strathclyde-led research develops world's highest gain high-power laser amplifier

The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.

The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

Camera on NASA's Lunar Orbiter survived 2014 meteoroid hit

29.05.2017 | Physics and Astronomy

Strathclyde-led research develops world's highest gain high-power laser amplifier

29.05.2017 | Physics and Astronomy

A 3-D look at the 2015 El Niño

29.05.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>